Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Advertising & Marketing

Sales

Legal & Regulatory

Acquisition & Integration

Goodwill impairment

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Teladoc

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company was founded on June 13, 2002, by George Byron Brooks and Gary Wald and is headquartered in Purchase, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teladoc reports solid Q4 growth, eyes revenue optimization strategies

Teladoc's Q4 performance showed revenue growth and margin focus, with BetterHelp contributing significantly to profitability.
The company's strategic focus on virtual care expansion and revenue optimization positions Teladoc for continued success in the healthcare market.
While facing internal restructuring challenges, Teladoc's emphasis on growth drivers and operational efficiency presents opportunities for future growth and market leadership.

Teladoc Health excels in Q1, eyes growth and efficiency

Teladoc Health's Q1 performance was strong, with revenue exceeding expectations.
The company is focused on efficiency, innovation, and driving value in virtual care.
BetterHelp segment showed growth and stability, with improving margins expected.
Opportunities exist to capitalize on ad pricing stability and consumer behavior trends.

Teladoc surpasses revenue expectations, focuses on innovation and growth

Teladoc's Q2 performance exceeded expectations, with strong revenue growth and improved margins in both segments. The company's strategic focus on whole-person care, weight management, and AI enhancements positions it well for future growth. Challenges include managing drug costs and private company valuations, while opportunities lie in virtual care demand and strategic M&A.
Teladoc's financial strength, commitment to innovation, and focus on efficiency improvements are key strengths driving its performance. The company's ability to navigate challenges and capitalize on opportunities in the evolving healthcare landscape underscores its resilience and growth potential.

Teladoc Health surpasses Q3 expectations, eyes margin expansion in '24

Teladoc Health's Q3 performance exceeded expectations, driven by revenue growth and margin improvements.
The company is focused on enhancing cost efficiencies, profitability, and driving margin expansion.
Stable pricing environment and strong client demand present opportunities for future growth.
Operational review and strategic initiatives position Teladoc for continued success in the healthcare sector.

Teladoc reports robust 2023 earnings, eyes growth amid marketing challenges

Teladoc delivered strong financial performance in 2023 with notable growth in adjusted EBITDA and revenue. The company faces challenges in BetterHelp marketing yields and delayed consumer engagement efforts.
However, Teladoc's strategic strengths lie in its long-term outlook for revenue growth, margin expansion, and cost-saving initiatives. Opportunities exist in optimizing sales force structure and capital deployment for future growth.
Overall, Teladoc's focus on profitability, growth optimization, and strategic capital allocation positions it well for sustained success in the telehealth industry.

Teladoc Health reports solid Q1 performance amidst revenue challenges

Teladoc Health's Q1 2024 performance showcased revenue growth in Integrated Care but challenges in BetterHelp segment revenue and margin management.
The company's financial strength, product portfolio, and cost initiatives position it well for growth opportunities and strategic market positioning.
Addressing challenges in ad spend management and focusing on international market efficiency are key to unlocking growth potential and improving financial performance.
Overall, Teladoc's performance, strengths, challenges, and opportunities reflect a dynamic landscape with strategic focus on sustainable growth and operational efficiency.

Teladoc Health reports Q2 revenue dip, EBITDA growth; addresses challenges

Teladoc Health's Q2 2024 performance showed mixed results with revenue decline but EBITDA growth. The company is leveraging strengths in patient safety and technology while addressing challenges in customer acquisition costs. Opportunities lie in operational efficiency, insurance coverage access, and international expansion.

Teladoc Health reports Q3 revenue decline but strategic growth

Teladoc Health's Q3 2024 performance reflects mixed results with revenue decline but strategic growth in the Integrated Care segment.
The company's focus on customer-centric strategies, technology, and clinical excellence positions it well for future success and market leadership.
Challenges in revenue decline and expense management require Teladoc Health to balance short-term financial performance with long-term growth objectives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002, by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in Purchase, NY.

Teladoc Health Inc (NYSE:TDOC) is down 7.3% to trade at $30.58 at last check, amid the latest tech selloff.

Can Teladoc Stock Recover From a Disastrous Start to 2022?

Who says there are no second chances? We may be close to seeing one such second chance appear with Teladoc Health Inc. ( TDOC , Financial), a pandemic darling that has fallen from grace.

Teladoc - Done or Overdone?

TDOC stock is like a falling knife now. Trying to catch Teledoc at this point is dangerous, risky and without any logic.

Teladoc Health Is Overvalued After Its Sell-Off

Teladoc is still growing, but whether its stock can rebound remains to be seen.

Is There a Light at the End of the Tunnel for Teladoc Stock?

Coinbase

Cisco Systems

Garmin

Cloudflare

SAP SE

Snowflake

Tech stocks to buy with temporary stock price dip create great buying opportunities for the long-term investors willing to hold for years. The post 7 Tech Stocks to Buy on Any Dips appeared first on InvestorPlace.

7 Tech Stocks to Buy on Any Dips

This healthcare stock looks like a bargain today.

Down 77%, This Stock Is a Buy Right Now

D.R. Horton

Canoo

GrowGeneration Corp

Novavax

Roblox

Redfin

Although the recent market volatility has presented some cheap prices, you should be leery about certain growth stocks to avoid. The post 7 Growth Stocks to Avoid Until the Market Crashes Again appeared first on InvestorPlace.

7 Growth Stocks to Avoid Until the Market Crashes Again

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC). The investigation concerns whether Teladoc has violated the federal securities laws and/or engaged in other unlawful business practices. Teladoc is a global provider of virtual care, transforming the access, cost, and quality dynamics of health care delivery. On April 27, 2022 Teladoc reported financial results for the three mon

Kirby McInerney LLP Continues Investigation of Shareholder Claims on Behalf of Teladoc Health, Inc. (TDOC) Investors

The good news: Today's problems look like temporary ones.

Teladoc Is Down 65%. Is It Time to Buy?

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Teladoc To Contact Him Directly To Discuss Their OptionsToronto, Ontario--(Newsfile Corp. - May 18, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC).If you suffered losses exceeding $50,000 investing in Teladoc stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/TDOC.

Teladoc Shareholder Alert

A tougher competitive landscape, plus a market less favorable to growth plays means a bad prognosis remains for TDOC stock. The post Why Teladoc Stock Does Not Have a Cure Right Now appeared first on InvestorPlace.

Why Teladoc Stock Does Not Have a Cure Right Now

General Motors

Let's take a look at two stocks that Ark Invest keeps buying, seemingly for reasons unknown.

Is Ark Invest Wrong About These 2 Stocks?

ARK Innovation ETF

Roku

Pandemic superstar fund, ARKK Innovation ETF, has been facing tremendous pressure as its stock continues to dip. Economic conditions and the losses recorded by its holdings have contributed to its woes. We believe buying the dip on ARKK is not wise at this time.

Cathie Woods Is In A Mess Right Now

Telemedicine has a sizable growth runway ahead.

Could This Healthcare Stock Be Berkshire Hathaway's Next Pick?

Viatris

They present very different kinds of bargains.

2 Stocks That Are Ridiculously Cheap Right Now

An analyst bucks the trend and lifts her price target on the stock.

Why Teladoc Health Flew 9% Higher on Friday

Teladoc has dropped more than 60% since the beginning of April, destroying billions of shareholder wealth. Business growth remained intact, but compressing margins and the need to spend massively on marketing are noteworthy issues.

Is Teladoc Stock A Buy Or Sell After April's Crash?

Peloton

Shopify

Once prosperous investments throughout the pandemic, the high-flying days for these stocks is well over in 2022.

Pandemic Winners Turned Losers: Should You Still Buy?

While there's no hiding from a tough first quarter, user metrics remained solid.

Teladoc's Stock Is on Life Support -- Can It Be Revived?

Amazon

Amazon Should Buy Teladoc Right Now -- Seriously

In this article, I explain my bullish thesis for Teladoc and Telemedicine. Teladoc's Q1'22 earnings weren't particularly impressive, but it's still too early to call it quits.

Teladoc: My Bullish Thesis

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Teladoc To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - May 9, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC).If you suffered losses exceeding $50,000 investing in Teladoc stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/TDOC.

Teladoc Update

New York, New York--(Newsfile Corp. - May 9, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. (NYSE: TDOC) ("Teladoc" or the "Company"). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Teladoc and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teladoc Health, Inc. - TDOC

Teladoc Health's (TDOC) bet on mental health service BetterHelp is likely to generate lower yield this year.

Teladoc (TDOC) Plunges 40.3% Since Q1 Earnings Beat: Here's Why

Corsair Gaming

Netflix

PayPal

Warner Bros Discovery Inc

These stocks fell enough after investors gave up, creating a tremendous buying chance for patient investors. The post 7 Sold-Off Stocks Ready to Surge From Here appeared first on InvestorPlace.

News for Teladoc Stock (TDOC)